Abstract
It is commonly recognized that hepatocellular carcinoma (HCC) accounts for approximately 60–80 % recurrence rate after 5 years of radiofrequency thermal ablation (RFA) operation, even in small HCC patients who experienced complete ablative operation [1, 2]. Generally, HCC is considered to recur more frequently from intrahepatic remnant micrometastasis within 1–2 years after RFA (defined as “early recurrence”). The late recurrence (2 or more than 2 years) mainly ascribes to the carcinogenic effect of underlying chronic liver disease [3]. Regardless of early or late recurrence, the prevention of tumor recurrence is extremely important, but unmet clinical administration. Except for improving the ablative effect with update techniques, adjuvant therapy after RFA may probably prevent the recurrence and improve the overall survival curve in small HCC patients. Moreover, treatments to prevent tumor recurrence should be conducted in accordance with the potential mechanisms of recurrence. Several clinical strategies including antiviral therapy with interferon and nucleoside analogues, immunotherapy, biotherapy, etc., have been recommended as the therapeutic options for the prevention of tumor recurrence after RFA.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903–12.
Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005;234:961–7.
Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.
Kim BK, Park JY, Kim dY, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008;28:393–401.
Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res. 2005;32:173–84.
Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308:1906–14.
Chuma M, Hige S, Kamiyama T, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44:991–9.
Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1929–35.
Dan JQ, Zhang YJ, Huang JT, et al. Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol. 2013;39:865–72.
Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–10.
Senturk H, Baysal B, Tahan V, et al. Long-term effect of interferon therapy in patients with HBeAg positive chronic hepatitis B infection. Dig Dis Sci. 2011;56:208–12.
Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516–23.
Lindahl P, Leary P, Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci U S A. 1972;69:721–5.
Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol. 1992;3:89–96.
Someya T, Ikeda K, Saitoh S, et al. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol. 2006;41:1206–13.
Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245:831–42.
Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458–65.
Suou T, Mitsuda A, Koda M, et al. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res. 2001;20:301–11.
Sakaguchi Y, Kudo M, Fukunaga T, et al. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005;48:64–70.
Hung CH, Lee CM, Wang JH, et al. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol. 2005;20:1553–9.
Qu LS, Jin F, Huang XW, et al. Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol. 2010;102:796–801.
Kudo M, Sakaguchi Y, Chung H, et al. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case–control study. Oncology. 2007;72 Suppl 1:132–8.
Ikeda K, Kobayashi M, Seko Y, et al. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: a retrospective study of hepatitis C virus-related liver cancer. Hepatol Res. 2010;40:1168–75.
Kudo M. Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology. 2008;75 Suppl 1:30–41.
Jeong S, Aikata H, Katamura Y, et al. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol. 2007;13:5188–95.
Weng DS, Zhou J, Zhou QM, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother. 2008;31:63–71.
Ma H, Zhang Y, Wang Q, et al. Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther. 2010;9:903–7.
Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 2014;134:342–51.
Liu Q, Zhai B, Yang W, et al. Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. Mol Ther. 2009;17:2049–57.
Saito K, Araki K, Reddy N, et al. Enhanced local dendritic cell activity and tumor-specific immunoresponse in combined radiofrequency ablation and interleukin-2 for the treatment of human head and neck cancer in a murine orthotopic model. Head Neck. 2011;33:359–67.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Gao, H., Chen, M. (2016). Adjuvant Therapy After Radiofrequency Ablation. In: Chen, M., Zhang, Y., Lau, W. (eds) Radiofrequency Ablation for Small Hepatocellular Carcinoma. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7258-7_10
Download citation
DOI: https://doi.org/10.1007/978-94-017-7258-7_10
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7257-0
Online ISBN: 978-94-017-7258-7
eBook Packages: MedicineMedicine (R0)